John Ulatowski, MD, PhD Director of Anesthesiology & Critical Care Medicine The Johns Hopkins Hospital and Health System table of contents greetings from the park A CREATIVE STAFF As I pen this note, the snow outside my window rushes by in torrents of white. Hopefully, 2 4 by the time you read this letter, the snows will have been replaced by warm spring rains and the emergence of new life in the garden. So, too, is it at Roswell Park, where new life emerges in the form of new programs and new trainees. You'll read in this issue of new programs and our continued efforts to recruit new trainees, of former trainees who have gone on to greater glory, and of new recruits with unlimited potential. Dr. John Ulatowski’s story highlights the role that RPCI played in the germination of his career in translational research. Just as a gardener plants seeds in the spring, the Roswell Park faculty works to germinate the seeds of curiosity within our trainees. John reminisces about these events, commencing with his humble beginnings in our master’s degree program, where the seeds of research curiosity were sown, through his PhD program, where he became enamored with the idea of pursuing a career in translational research. His story exemplifies what we do best at Roswell Park: training translational scientists. I look forward to meeting more inspired and inspiring trainees like John in the years to come. Don't forget to do your part by recommending Roswell Park as a first choice for clinical and basic scientific training…and keeping us informed of your professional and personal milestones. Arthur M. Michalek, PhD, FACE Senior Vice President, Educational Affairs Dean, Roswell Park Graduate Division, University at Buffalo 10 6 14 22 23 24 Managing Editor Colleen M. Karuza faculty interview alumni spotlight Senior Copywriter & Editor Sue Banchich Creative Services Director Benjamin Richey Graphic Production Manager Hillary Banas rpci headliners research & technology Photography Bill Sheff Benjamin Richey ADMINISTRATION President & CEO Donald L. Trump, MD, FACP it’s academic forum and function Senior Vice President Educational Affairs Dean, Roswell Park Graduate Division, University at Buffalo Arthur M. Michalek, PhD, FACE Vice President Emeritus, Educational Affairs Edwin A. Mirand, PhD, DSc class notes extracurriculars Vice President, Marketing, Planning & Public Affairs Laurel A. DiBrog Vice President, Development Cindy A. Eller Published three times a year. All rights reserved. No portion of this magazine may be reproduced without written permission. To receive a free subscription, please email [email protected]. To learn more about giving opportunities, please call the Development Office at 716-845-4444. FACULTY INTERVIEW: WILLIAM CANCE, MD, SURGEON-IN-CHIEF What attracted you to Roswell Park? Roswell Park is on a stellar trajectory across the board in oncology, and it offers the opportunity to do clinical work and to translate basic research into clinical trials. I’m really excited about new types of clinical trials, particularly with small-molecule inhibitors. We’re uniquely positioned at Roswell Park to be able to take those abilities into the clinic—and a lot of those new therapies will be less toxic, because they’re more selective. I am also developing a natural collaboration with Dr. Andrei Gudkov [The Garman Family Chair in Cell Stress Biology and Senior Vice President of Basic Science]. He was kind enough to let me locate my lab next to his and has kindly shared his resources with our group. He’s one of the most brilliant people I’ve ever met. facultyinterview : William Cance, MD “ There’s such pride in, and such a love of, Roswell Park in the community. It’s a terrific place to be. “ 2 | facultyinterview F From the time he was a fourth-grader, William Cance knew he wanted to be a surgeon. In high school, he found a mentor in surgical oncologist Dr. Warren Cole, Past President of the American Cancer Society. Dr. Cance’s decision to specialize in surgical oncology intensified after his roommate at Duke University died of sarcoma. “I saw firsthand the devastation of cancer,” he reflects. Recently appointed Chair of Surgical Oncology and Surgeon-in-Chief at Roswell Park, Dr. Cance directs the Department of Surgical Oncology, oversees operating room and surgical services, and serves as principal investigator of a surgical oncology training grant. He served previously as Chair of the Department of Surgery and Associate Director of Shands Cancer Center at the University of Florida. Here he answers questions about his hopes for Roswell Park. How do you foresee the medical community coping with the ongoing shortage of physicians, including surgeons? The shortage of surgeons is already being felt in rural areas, and it will be felt all over as Baby Boomers retire and the need increases. Not enough surgeons are being trained; there are nowhere near enough surgical oncologists to do all the cancer surgery in the country, so most cancer surgery will continue to be done by general surgeons who were trained during their residency. This has increased the importance of Roswell Park’s educational mission. The leaders in surgical oncology will be fellowship-trained surgical oncologists, who will lead the other surgeons who will be doing cancer surgery. We have a tremendous fellowship program at Roswell Park, led by Dr. Stephen Edge, that provides this special expertise in surgical oncology. We have great faculty in surgery; for example, Dr. John Kane is on the training committee of the Society of Surgical Oncology. So we have the training infrastructure—and as we train fellows, we will be recruiting some of them to join us at Roswell Park. You brought several colleagues to Roswell Park with you. Please give an example of their potential contributions to the Institute’s mission. Drs. Vita Golubovskaya and Elena Kurenova are Associate Professors of Oncology and will be the nucleus of our lab efforts. Both are accomplished scientists with expertise in cell and molecular biology. They will be leaders of our departmental translational research efforts. Dr. William G. Cance CA R E E R H I G H LI G HTS ✯ MD, Duke University School of Medicine – 1982 ✯ Fellow of the American College of Surgeons ✯ President, Society of Surgical Oncology ✯ Clinical Interests: surgical oncology, endocrine surgery ✯ Research Interest: the biology of focal adhesion kinase (FAK), which plays a key role in protecting cancer cells from programmed death (apoptosis) ✯ Chief Fellow, Surgical Oncology, Memorial Sloan-Kettering Cancer Center, 1989-90 ✯ Hector MacLean Distinguished Professor of Cancer Research, University of North Carolina Lineberger Comprehensive Cancer Center – 2002 Dr. Sergei Kurenov is an engineer who did simulation for the MIG-29 aircraft in the former Soviet Union. Now he does surgical simulations. He’s bringing with him a postdoctoral computer programmer, and they will collaborate with Dr. James Mohler, Dr. Khurshid Guru and members of Roswell Park’s robotic surgery simulation group to make it even stronger. Dr. Kurenov will also be working with the minimally invasive surgery program, which Dr. Mohler has done a great job of getting off the ground. What are your principal goals as you assume your new role? I look forward to coordinating and enhancing Roswell Park’s surgical services and translational research efforts across all the disciplines. Surgery remains a mainstay of oncologic practice, and we need to continue to keep abreast of advances in surgery, patient safety and patient outcomes. I’m also anxious to strengthen our academic mission through clinical trials while delivering the highest-quality cancer care. There’s such pride in, and such a love of, Roswell Park in the community. It’s a terrific place to be. 3 John Ulatowski’s Fantastic Voyage R Roswell Park Cancer Institute was the launching point for John Ulatowski’s first voyage into the bloodstream. From those early days of graduate school when he explored the development of blood cells, he journeyed on into anesthesiology and neurology. Along the way, he earned worldwide recognition for advancing our understanding of the physiological processes that affect recovery after a stroke or brain injury. Today Dr. Ulatowski is Director of Anesthesiology and Critical Care Medicine (ACCM) of The Johns Hopkins Medical Institutions, overseeing a department with 115 faculty, 75 residents, and 24 CRNAs, who serve more than 70 anesthetizing locations in two major hospitals and surgicenters every day. When he came to Roswell Park in 1975 to earn a master’s degree in natural sciences, he planned to apply to medical school the following year. “But my experience at Roswell Park was extremely stimulating, and convinced me that a career in research would be as rewarding as a career in medicine,” he says, “so I stayed for a PhD in cell physiology.” That decision led to two important connections, first with Michael McGarry, PhD—then Director of the Department of Laboratory Animal Resources, now Vice President of Preclinical Studies at Medelis. Dr. McGarry “had an interest in experimental hematology, particularly in the Photo courtesy The Johns Hopkins Medical Institutions immune response as it pertained to the development of a blood cell called the eosinophil,” recalls Dr. Ulatowski. His working relationship with Dr. McGarry, coupled with his experiences as a part-time lab technician in Buffalo General Hospital’s hematology laboratory, “got me interested in studying how blood cells develop.” The second connection, with James Zucali, PhD, his thesis advisor, led him to reconsider a career in medicine. Dr. Zucali, he says, “saw the value of having an MD in addition to being a basic science researcher, for ease of translational work—taking science from the bench to the bedside.” Heeding Dr. Zucali’s advice, Dr. Ulatowski completed medical school at the University at Buffalo, setting his sights on a relatively unexplored area of inquiry—the brain. “I found that very challenging,” he explains, “so I trained as a neurologist at the University of Maryland. 4 | alumnispotlight “I was then attracted to Johns Hopkins by an opportunity to train as an intensive-care physician focused on brain injury and spinal cord injury. Johns Hopkins had a nationally leading program in that area, and it was administered through the Department of Anesthesiology.” At the suggestion of Dr. Mark Rogers, then department chair, Dr. Ulatowski pursued a second fellowship in anesthesiology. The fusion of neurology and anesthesiology has given him an unusual perspective in addressing yet-unanswered questions about the brain: “How do we preserve brain under stressful conditions, such as when a patient undergoes anesthesia or has a direct trauma to the body? We are finding that there are many secondary effects of generalized injury to the body that affect brain function, and that’s an extremely important area of research. “Now I’m studying the endpoint of what a red cell produces— hemoglobin—in a state that is free to float in the bloodstream. I’m excited about the possibility that those kinds of plasma-based, oxygen-carrying compounds might be able to deliver oxygen to ischemic or injured brain better than blood cells themselves, because many times a fluid-based protein can get through the small channels of the bloodstream to critical areas of the brain better than blood cells themselves can.” It’s interesting, he reflects, that many of the questions he seeks to answer today, 30 years after graduate school, have led him to concentrate once again on the development of red blood cells—the very work that first commanded his attention at Roswell Park. In the hot seat Dr. Ulatowski answers questions about the challenges of modern medicine and the keys to success. How can the United States cope with the ongoing critical shortage of anesthesiologists? Given the demands of the healthcare system now and in the future, I think it’s wise to create a healthcare workforce matrix to meet demand. The anesthesiologist should be at the top of the information pyramid. However, nowadays we’re working more and more with mid-level providers, such as nurse-anesthetists and anesthesiologist assistants. The way to counteract the shortage of anesthesia providers is to consider, in some way or another, training all three. Will we see more physicians earning both an MD and a PhD to narrow the gap between basic and clinical research? It’s extremely difficult for someone to study in the basic sciences and then progress through clinical medicine to obtain an MD while staying fresh and competitive. Only a few people who do that can remain at the top of their field. I think a better model for the future is to have a combination of dedicated basic scientists and clinician-scientists who work closely together in the translational, bench-to-bedside component. That makes much more sense for the future, by allowing individuals to focus their time and expertise on one element of the healthcare paradigm that ultimately brings new discovery to the clinical forefront. The key element is to have professionals who communicate and work together in a community of scientists rather than having those individuals represented in one person. What laid the foundation for your professional achievement? The tremendous dedication of those who allowed me the opportunity to do this, starting with my parents, and then all the individuals who have been my mentors throughout my career. And being affiliated in my career with organizations that allowed me to grow. My success is really the success of institutions that focus on developing people to their fullest. Roswell Park and Johns Hopkins have been two of those. 5 F acult y Not es Faculty Notes ❶ ❷ ❶ Anubha Bharthuar, MD, Clinical Fellow, Department of Medicine, discussed “Quality of Life in Patients with Advanced Pancreatic Cancer Receiving Gemcitabine, Capecitabine, and Bevacizumab: Results from a Prospective Multicenter Phase II Trial,” at the Fifth Annual Meeting of the International Society of Gastrointestinal Oncology, held in Virginia. ❷ Shousong Cao, MD, Cancer Biology, has been appointed a Visiting Professor at Forth Military Medical University in Xi’an, Shaanxi Province, China, and has also been named to the editorial board of The Open Colorectal Cancer Journal, published by Bentham Science Publishers, Ltd. ❸ K. Michael Cummings, PhD, Chair of the Department of Health Behavior, was recognized in March 2009 as a leader in global tobacco control when he received the American Cancer Society’s Luther L. Terry Award for Outstanding Research at the 14th World Conference on Tobacco and Health in Mumbai, India. The Award is named for the late U.S. Surgeon General who led the landmark 1964 Surgeon General’s Report connecting tobacco use to lung cancer and other illnesses. ❹ Luqman Dad, MD, Radiation Medicine, is one of three people who were elected recently to two-year terms on the Executive Committee of the Association of Residents in Radiation Oncology (ARRO). ARRO is the resident organization within ASTRO, the American Society for Radiation Oncology, and represents nearly 600 radiation oncology residents in the U.S. ❺ Michelle Detwiler, MS, Project Coordinator, Cell Stress Biology, has been elected President of the Association of Biomolecular Resource Facilities, an organization with a membership of more than 1,000 scientists. ❻ Kelli Bullard Dunn, MD, FACS, FASCRS, Department of Surgery, has been awarded the Victor W. Fazio, MD, MS, Award for Editorial Excellence by the editors of Diseases of the Colon & Rectum. Editor-in-Chief Robert Madoff, MD, commended Dr. Bullard Dunn for “her astute clinical acumen, scientific expertise and superb editorial judgment.” 6 | rpciheadliners ❸ ❹ ❺ ❼ Theresa Hahn, PhD, Assistant Member, Department of Medicine, presented “Clinical and Genetic Factors Underlying Acute Bone Mineral Density Loss by 100 Days after Blood and Marrow Transplantation: A Potential Early Regimen-Related Complication,” for a session on Clinical Transplantation – Transplantation Regimen, at the 2008 annual meeting of the American Society of Hematology, held in December in San Francisco. ❽ Wen Wee Ma, MBBS, Assistant Professor of Oncology, was quoted recently in HemOnc Today about lack of progress in the treatment of pancreatic cancer. He pointed out that since the approval of gemcitabine a decade ago, “the field has been trying to mesh different combinations [of drugs] with gemcitabine. The most recent results presented by Kindler and colleagues at 2008 ASCO showed that gemcitabine and bevacizumab with erlotinib or cetuximab doesn’t have sufficient activity in advanced diseases.” Dr. Ma added that he sees a need for greater attention to the potential of individualized therapies. ❾ Enrico Mihich, MD, Distinguished Member of Roswell Park’s Department of Pharmacology and Therapeutics, has been named a Fellow of the American Association for Advancement of Science. A member of the Roswell Park faculty since 1957, Dr. Mihich is a nationally recognized expert in the development of therapeutics, Past President of the American Association of Cancer Research and a member of the US National Cancer Advisory Board. 10 Kena Miller, RN, MSN, FNP, Department of Medicine, discussed “An Update on Myeloma: The Latest in Research and Treatment,” a Continuing Education program for community practice nurses, presented in November 2008 by the Leukemia and Lymphoma Society. She is also a co-author of “Management of Side Effects of Novel Therapies for Multiple Myeloma: Consensus Statements Developed by the International Myeloma Foundation’s Nurse Leadership Board,” published in the Clinical Journal of Oncology Nursing, Supplement to Vol. 12, No. 3. ❻ ❼ ❽ ❾ Renal function may be compromised in some patients as a result of radiation treatment to the abdomen—but the effects may not be noticed until a year or more after the end of radiotherapy (RT), according to a study led by 11 Gary Yang, MD, Associate Professor of Radiation Medicine. Dr. Yang and his team tracked 129 patients who underwent 3D conformal radiation therapy for GI cancers, finding that some experienced renal decline a year or more after the end of RT. The results of their study, presented at the annual meeting of the American Society for Therapeutic Radiology and Oncology, represent the first quantification of the effects of RT on kidney function, and underscore the need for longer patient monitoring after RT has ended. Investigators who contributed to the study include Kilian Salerno May, MD, Radiation Medicine; Rameela Chandrasekhar, Biostatistics; Leayn Flaherty, RPA-C, Radiation Medicine; Richard Russo, CMD, RTT, Radiation Medicine; and Gregory Wilding, PhD, Assistant Chair, Biostatistics. 10 11 Pili heads GU Section Nationally recognized medical oncologist Roberto Pili, MD, has been appointed Professor of Oncology, Chief of the Genitourinary Section and Co-Leader of the Genitourinary Program. He comes to RPCI from The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, where he served as Associate Professor of Oncology and Urology. Nobel Laureate Roger Tsien to present Dave Lecture at RPCI Roger Tsien, PhD, winner of the 2008 Nobel Prize in Chemistry, will present the annual Dave Memorial Lecture at RPCI, Thursday, April 23, 2009, at 9 am in the Hohn Lecture Hall of the Research Studies Center. He will discuss “Optical and MR Imaging of Tumors In Vivo with Activatable Cell-Penetrating Peptides.” Dr. Tsien is an investigator with the Howard Hughes Medical Institute, Professor of Pharmacology at the University of California at San Diego School of Medicine, and Professor of Chemistry and Biochemistry at the University of California at San Diego. Established to honor the late Chandrakant V. Dave, PhD, who served on the Pharmacology faculty at RPCI, the Dave Lecture Series is organized by graduate students of the Molecular Pharmacology and Cancer Therapeutics Department. 7 RPCI: Industry Leader in Buffalo Niagara The Buffalo Niagara Partnership (BNP) has recognized RPCI as an innovative leader in the region’s life sciences industry. Donald Trump, MD, RPCI’s President & CEO, accepted the INNOVATE Buffalo Niagara Award for Life Sciences on behalf of the Institute at a luncheon held Jan. 28, 2009. Among other achievements, the BNP cited RPCI’s role as “a source of important new products and processes for use in the fight against cancer.” The awards singled out Buffalo Niagara’s “most groundbreaking and inventive companies” in five industry sectors: advanced manufacturing, agribusiness/food processing, professional services, life sciences and logistics. Twenty-one finalists were chosen from among 60 companies nominated. There’s No Stopping Buffalo Christine Sable is a powerful spokesman for RPCI’s new fundraising campaign, NEVER STOP BUFFALO™. After receiving a diagnosis of advanced-stage ovarian cancer, the Lancaster, PA, resident enrolled in a clinical trial of a new ovarian cancer vaccine developed by Kunle Odunsi, MD, PhD, Surgeon in Gynecologic Oncology and Co-Leader of the Tumor Immunology and Immunotherapy Program at RPCI. Community donations to RPCI were critical for initial research on the vaccine. In Ms. Sable’s case, the vaccine was administered after conventional chemotherapy, and it quickly improved her immune system’s ability to fight off recurrence of the disease. Five years later, she’s still cancer-free and has experienced no side effects. “Roswell Park is such an incredible place,” she says. “It has given so many people hope, and given them their lives back.” Funding from NEVER STOP BUFFALO and similar campaigns will help fast-track the development of other new treatments at RPCI. Dollars raised by the campaign will be awarded competitively in the form of grants to fund research proposals submitted by RPCI physicians and scientists to the Institute’s Research Advisory Committee. Grants will be awarded to projects showing the greatest potential to improve cancer prevention, diagnosis and care. “Christine Sable is just one of thousands of patients who arrive at Roswell Park each year looking for lifesaving treatments for the hundreds of cancers we treat,” says Donald Trump, MD, FACP, President & CEO. “Now, more than ever, we need our community’s continued support. We will never stop searching, never stop healing, and never stop fighting until cancer is defeated.” To learn more, or to donate to NEVER STOP BUFFALO, call 716-845-4444, or make a secure online gift at www.neverstopbuffalo.com. 8 | rpciheadliners as Powerful Medicine Music is powerful medicine for Marc Murray, a 25-year-old patient who came to RPCI for a bone marrow transplant after a diagnosis of acute myeloid leukemia. During his long recovery, he connected with Stuart Fuchs, a multi-talented musician, member of the gypsy jazz band Babik, and an artist-in-residence at RPCI, and the two began playing guitar together during informal jam sessions in the hospital. It was a time of rediscovery for Mr. Murray, who had once played guitar regularly before “letting it lapse” several years ago. Mr. Fuchs inspired him to pick it up again, and it has been both physically and spiritually therapeutic. “Some of the medicines I’m on cause shaking in my hands, and playing the guitar helps with that,” Mr. Murray says. “As a result of the chemotherapy, my hands peeled, and I lost all the calluses I’d built up on my fingertips, so Stuart helped me with some exercises to build them up. “The guitar is soothing,” he adds, “and there’s music for every kind of emotion. You can play whatever you feel.” That’s the underlying principle of the new Arts in Healthcare initiative of the University at Buffalo’s Center for the Arts. Launched in the fall of 2008, the program places artists at RPCI and Women’s and Children’s Hospital of Buffalo so they can share their talents with patients and visitors. In addition to Mr. Fuchs, RPCI’s team includes visual artists Ann Frank, Barbara Murak and Pragna Hathi Wood; actor/storyteller Joy Scime; and dancer Sheila Dollas. Their work is funded by The John R. Oishei Foundation and gifts to the Roswell Park Alliance Foundation. Margarita Coyne, RN, BSN, Director of Patient Services, helped get the program off the ground. She says interacting with artists provides patients with a welcome distraction, facilitating communication and reminding patients and families that “there are other things going on in life.” And studies show that cancer patients who participate in art activities in a hospital setting report feeling less bored, sad and anxious. Debra Miga, Assistant Coordinator of Volunteer Services, notes that patients who have heard about the artists-in-residence program are starting to request that the artists visit them in their rooms or specific clinics. That’s no surprise to Mr. Fuchs, who helps them explore their emotions through many styles of music, from the tunes he plays on a 10-stringed Andean churango to the deep tones he creates with an Australian didgeridoo. Creating art or music gives patients “control over their immediate environment, even if just for a little while,” says Mr. Fuchs. “There is a real magic that happens when patients engage in the creative process. They enter the present moment, which allows them to put their troubles aside while they express themselves creatively. The activity becomes a reflective healing process, a mirror into their soul.” Marc Murray (left) with Artist-in-Residence Stuart Fuchs The Arts Council in Buffalo & Erie County has honored RPCI President & CEO Donald Trump, MD, FACP, as a Trailblazer for his contributions as “a pioneer, legacy maker and innovator in the Western New York arts and cultural community.” He shared the award in the Artist and Healthcare Initiative category with Cheryl Klass, President of Women & Children’s Hospital of Buffalo. Both institutions are partners in the Arts in Healthcare Initiative of the University at Buffalo’s Center for the Arts, which takes local artists into the healthcare setting to engage patients in music, drama, and the visual arts. The awards were presented at the 23rd Annual Arts Award Program, held March 20, 2009. Other Trailblazer honorees included Angelo Fatta, PhD (Philanthropist/Patron of the Arts), Michael Morgulis (Artist/Entrepreneur), and Artpark & George Osborne (Programming and Leadership). feature | 9 Adjei leads NSCLC trial Let There Be Light! pdt PDT Center Receives Federal Funding in Excess of $10 Million Alex A. Adjei, MD, PhD, Senior Vice President of Clinical Research and the Katherine Anne Gioia Chair in Cancer Medicine, is chairing a newly launched national clinical trial that is the first ever to focus on whether biomarkers can help guide therapies for lung cancer. The large National Cancer Institute (NCI) trial for nonsmall cell lung cancer, called MARVEL (Marker Validation for Erlotinib in Lung Cancer), seeks to validate whether a biomarker can predict clinical benefit in the disease. It will establish whether a biomarker can identify a target, epidermal growth factor receptor (EGFR), and the effectiveness of drugs in blocking the target, thus re-defining treatment options for lung cancer patients. NCI Director John Niederhuber, MD, says MARVEL is “of major importance, because it could define, based on a single test, the best therapy for this disease.” Approximately 1,200 lung cancer patients will be tested for a high copy number of the EGFR gene by Fluorescent in Situ Hybridization (FISH) status of the marker and will be randomized based on the outcome of the test. After receiving initial standard chemotherapy, patients who are both EGFR-positive and EGFR-negative will receive either erlotinib or pemetrexed, two approved treatments for advanced lung cancer. The study will help understand the mechanisms of the drugs and identify patients who will benefit most from these targeted therapies. Alex Adjei, MD, PhD with Sarah Burke, RN, MSN, Clinical Research Nurse Marker Validation for Erlotinib in Lung Cancer “The MARVEL trial is the result of collaboration among several national healthcare organizations, including the U.S. Food & Drug Administration, NCI cooperative groups, the biomarker industry and the pharmaceutical industry,” notes Dr. Adjei. “All are focused on the goal of providing new, more effective treatments for lung cancer patients.” It’s estimated that 215,020 people will be diagnosed with lung cancer this year, and 161,850 will die of the disease, making lung cancer the numberone cancer killer. Non-small cell lung cancer comprises about 85-90% of all lung cancers diagnosed. Read more about the trial on the NCI website, at www.cancer.gov/newscenter/pressreleases/MARVELrelease. 10 | researchandtechnology A A five-year, $10.2 million grant from the National Cancer Institute (NCI) will help RPCI continue its pioneering studies in photodynamic therapy (PDT). The Institute is known worldwide for the development of PDT, which uses red laser light to trigger a photosensitizing drug that collects in tumor cells. When activated by the laser, the drug kills the cancer cells. RPCI has received uninterrupted NCI funding for its PDT program since 1992—a remarkable achievement. Ravindra Pandey, PhD, Distinguished Member, PDT Center, will continue his work in developing novel agents for optimization of PDT and tumor imaging. Led by principal investigator Barbara Henderson, PhD, Professor of Oncology and Director of the PDT Center, Department of Cell Stress Biology, the program project grant explores mechanisms and strategies for making PDT more effective in treating cancer. The program consists of five projects, supported by four technical, statistical and administrative core units: Sandra Gollnick, PhD, Professor of Oncology, PDT Center, will examine how PDT can affect mechanisms of tumor immunology Heinz Baumann, PhD, Professor of Oncology, Department of Molecular and Cellular Biology, will explore molecular pathways for optimizing PDT. Nathalie Zeitouni, MD, Interim Chair, Department of Dermatology, will investigate mechanisms of PDT in patients being treated for skin cancer. “Roswell Park has a long-standing benchto-bedside approach to PDT that facilitates an understanding of the underlying mechanisms of the process while translating that knowledge into novel treatments,” says Dr. Henderson. Adds Donald Trump, MD, FACP, President & CEO of RPCI, “The very positive review and awarding of funding for this program are a testament to the outstanding science conducted at Roswell Park. NCI program project grants are highly sought by cancer centers. Receipt of this NCI grant demonstrates the cutting-edge science in this pioneering Roswell Park research program. The grant continues support of a broad-based, multidisciplinary team approach to PDT cancer research and discovery at RPCI.” Nestor Rigual, MD, Associate Professor of Oncology and Attending Surgeon, Department of Head & Neck Surgery, and Merrill Biel, MD, Clinical Associate Professor, University of Minnesota, will conduct clinical trials using PDT for the treatment of early-stage cancers of the head and neck. 11 Robotics “Patients have indicated that the overall quality of their life after cancer surgery is as important as how long they survive.” Khurshid Guru, MD Mounting a First-Line Defense Against Infections Brahm Segal, MD, right, with graduate students David Lewandowski and Nicole Rall T he National Institute of Allergy and Infectious Diseases (NIAID) has awarded a five-year, $2,176,043 research grant to RPCI to examine mechanisms of acute inflammation. Brahm Segal, MD, Chief of Infectious Diseases, is the principal investigator. “Inflammation helps the body defend against infections, such as bacteria, viruses and fungi,” explains Dr. Segal. “Just as it is important to stimulate inflammation to control infections, it is also necessary to turn off the inflammatory response to avoid tissue injury and allergy. Excessive inflammation is associated with a broad range of diseases, including cancer, diabetes and autoimmune diseases.” “Inflammation helps the body defend against infections, such as bacteria, viruses and fungi.” Dr. Segal and colleagues from Vanderbilt University Medical Center will analyze NADPH oxidase (nicotinamide adenine dinucleotide phosphate-oxidase), an enzyme complex that helps defend against infections. The study is expected to offer new insights into chronic granulomatous disease (CGD), a rare inherited disorder of the NADPH oxidase that is characterized by recurrent infections and inflammatory complications. “Future studies supported by this grant will help us understand how NADPH oxidase controls inflammation,” says Dr. Segal. “Knowledge gained about how the body regulates inflammation may help us understand disorders of inflammation and develop better treatments.” 12 | researchandtechnology Pioneering Robotic Surgery Adds Life to Years Bladder cancer patients treated with state-of-the-art robot-assisted surgery at RPCI report that their quality of life returned to normal within six months, according to a study conducted by Khurshid Guru, MD, Director of Robotic Surgery. The study was published in the British Journal of Urology International. Pioneered at RPCI, robot-assisted cystectomy provides patients with a less-invasive treatment option that has several potential advantages over traditional open surgery, including less postoperative pain and fewer days in the hospital. The prospective study is the first to examine the quality-of-life benefits of the surgical technique. “Patients have indicated that the overall quality of their life after cancer surgery is as important as how long they survive,” says Dr. Guru. “This study helps us understand the patient’s physical, social, emotional and functional well-being after surgery.” Quality of life was examined using the Functional Assessment of Cancer Therapy questionnaire with 34 patients who underwent robot-assisted surgery between January 2006 and December 2007. Patients were monitored according to National Comprehensive Cancer Center guidelines. The average age of the patients was 65 years; 88% were men. Of all patients, 13% received chemotherapy after surgery. Quality-of-life issues were assessed at 1-, 3- and 6-month intervals. The study found that physical well-being had decreased significantly by the first follow-up visit, due to the immediate impact of surgery. However, six months later, patients reported that their physical activities were comparable with their pre-surgery activities. Emotional scores were statistically higher after surgery, indicating that feelings of sadness and anxiety appeared to be alleviated by the minimally invasive surgery and rapid recovery. Scores for social and family support remained uniformly high. Says Dr. Guru, “Robot-assisted surgery continues to demonstrate its efficacy as a treatment for bladder cancer patients and has now shown its value to patients as they return to life after cancer.” 13 Reinventing the postdoc experience A FAQ page will provide community information for out-of-towners. Dr. Kisailus notes that many postdocs are married and have children, “so they have to think about housing, daycare and school systems.” The website will serve double duty as a bulletin board to identify and connect with peers who share interests, and to showcase achievements for prospective employers. • A handbook outlining the responsibilities of postdoctoral scholars and their RPCI mentors, and apprising them of workshops and other training-enhancement opportunities. Adam Kisailus, PhD (center), with postdocs Kjerstin Owens (left) and Gaia Bistulfi R PCI’s postdoctoral scholars “have their fingers on the pulse of what’s going on in science,” observes Adam Kisailus, PhD. “They’re on top of the literature, they have fresh ideas and a fresh outlook, and they bring enthusiasm and energy into the classroom. We rely on them for our scientific research, but at many universities, they’re almost invisible.” Today RPCI’s Division of Educational Affairs is focusing more sharply on their needs and interests with a plan informed largely by Dr. Kisailus’ own postdoctoral experience. After earning a PhD in molecular biology from Georgetown University, he came to RPCI to investigate focal adhesion kinase activity in the lab of Irwin Gelman, PhD, now Interim Chair of Cancer Genetics. Dr. Kisailus says he and his fellow postdocs “found there were things we wanted to do as a community.” The timing was good, too! Arthur Michalek, PhD, Dean and Senior Vice President of Educational Affairs, and Craig Johnson, Director of Graduate Admissions and Summer Research Programs, had just determined that there was a need for greater postdoc support. Dr. Kisailus’ interest led to his appointment last summer as Assistant Dean. The new initiative will provide RPCI’s postdocs with more training in such areas as grant writing, ethics, teaching, and career paths, to supplement the strong research training they receive from mentors. Dr. Kisailus will oversee programs and services designed to provide them with one-stop shopping: • A Web portal (www.roswellpark.org/Site/Education/postdoc) where candidates can learn about, and apply for, postdoctoral opportunities at RPCI. 14 | it’s academic • The Science Teaching Experience for Postdoctoral Scholars (STEPS), a program aimed at developing teaching skills, from creating a syllabus to adapting course content for high school or college students. Dr. Kisailus says the program might evolve into a local certificate program that postdocs could list among other credentials on their CVs. • APoDS—the Association of PostDoctoral Scholars—an existing organization that sponsors social events, presents guest speakers, and organizes poster sessions and other professional activities. • Networking opportunities within the biotech corridor of the Buffalo Niagara Medical Campus. Postdoctoral candidates and scholars can reach Dr. Kisailus at 1-716-845-5944 or via email at [email protected]. Front and center: the postdoc as lecturer “Most postdoctoral scholars are expert in one field, but they may lack experience in teaching or in presenting material at a seminar,” says Dr. Kisailus. To fill that gap, soon they’ll be able to strengthen their teaching proficiency by presenting a lecture for Oncology for Scientists. Required of all RPCI graduate students, the two-semester course typically enrolls 40-50 students and is coordinated by AnneMarie W. Block, PhD, Director of the Clinical Cytogenetics Laboratory and Associate Professor of Oncology. Dr. Block says RPCI faculty present most of the lectures, but Dr. Kisailus “thought we could include the postdocs, because they’re not that far removed from the graduate experience. They appreciate a good lecture, and they know how to put one together.” Medical Dosimetry Program: “very competitive” – and it’s accredited RPCI’s Chief Physicist, Matthew Podgorsak (center), with medical dosimetrist trainees (l. to r.) Mohamed Smith, Mobeen Tamimi, Barry Melancon, and Ashkan Parniani T here’s growing demand in the U.S. for medical dosimetrists, who calculate the radiation dosage for cancer patients and use 3D graphics and patient imaging to determine the best way to deliver radiation to the tumor site. RPCI’s Medical Dosimetry Training Program stands out as one of only 12 in the nation accredited by the Joint Review Committee on Education in Radiologic Technology (JRCERT). That seal of approval is important for trainees, because completion of a JRCERT-accredited program is now a prerequisite for taking the Certified Medical Dosimetrist Exam. Here Matthew Podgorsak, PhD, Chief Physicist at RPCI, discusses what it takes to achieve accreditation—and why it’s important. What’s the rationale behind the new CMD Exam prerequisite? The Medical Dosimetrist Certification Board is trying to ensure that educational programs are meeting the challenges of the more advanced technology that’s being used in cancer therapy today. Professional dosimetrists need to have proper practical training, but they also need a basic understanding of the theory and principles behind the technology—something they can get only by attending an accredited medical dosimetry training program. What elements of the training program came under review during the accreditation process? JRCERT reviewed a number of standards, from ethics issues to the number of didactic courses that must be offered. We also had to show that our students are mentored by practicing medical dosimetrists in both on-the-job and laboratory training. Our students interact with not only the seven medical dosimetrists on staff, but also physicists, radiation oncologists, and business professionals. This gives students a well-rounded educational experience—and that’s important, because when they are practicing professionally, they will have to interact with many other people within the discipline. How many students apply to the program each year? There were 30-40 applicants for next year’s class [fall of 2009], and we can enroll only six per year, so it’s a very competitive program. The number we can take is based in part on student access to mentors and equipment, especially the planning workstations. We have several workstations dedicated for student use, and are in the process of acquiring others, with the implied hope that we can increase our enrollment. What’s the attraction to this field? Medical dosimetrists are scientists, but they also have to have a certain artistic flair in order to visualize the best way of using the available technology to deliver the radiation dose to our patients so they get the best care. There are many degrees of freedom involved, so you need dosimetrists who are experienced, but who also understand the basics of what they’re doing. That’s key, and that’s what we have at Roswell Park. For more information about RPCI’s Medical Dosimetry Training Program, visit www.roswellpark.org/Medical_Dosimetry_Training. 15 The Head of the Class Two of the three top research projects recognized at the Jan. 22, 2009 Medical Student Research Forum at the University at Buffalo were based at RPCI, reports Arthur Michalek, PhD, FACE, RPCI’s Senior Vice President for Educational Affairs. The U.B. School of Medicine sponsors the annual forum as one way of “encouraging and supporting research training for medical students,” notes Dr. Michalek, who served as a judge for the event. Stephan Munich (2011) took second place for “Administration of Chemotherapeutic Agents Enhances the Therapeutic Effect Induced by a Survivin Molecular Mimic Vaccine Against Human Glioma,” which he completed under the guidance of Robert Fenstermaker, MD, Clinical Chair of Neurosurgery, and Michael Ciesielski, PhD, Assistant Member in Neurosurgery. Matthew Sheldon tied with two other presenters for third place. He completed his project, “Apical Margins after Robot-Assisted Radical Prostatectomy: Does Technique Matter?” under the direction of Khurshid Guru, MD, Director of Robotic Surgery; James Mohler, MD, Chair, Urologic Oncology, and Leader of the Prostate Program; Hyung Kim, MD, Urologic Oncology; and Gregory Wilding, PhD, Assistant Chair, Biostatistics. Low Cancer Incidence Among Seneca Nation First place was awarded to Andrew Baschnagel (2009), an applicant to RPCI’s Radiation Medicine Residency Program. His project, completed at the National Institutes of Health, addressed “Urinary c-MET and HGF Levels as an Indicator of Disease Progression in Glioblastoma Multiforme Patients.” shelfLIFE Check out these titles written or edited by RPCI faculty: Mitochondria & Cancer Interferons: Current Status by Keshav Singh, PhD Member, Cancer Genetics (New York: Springer Publishing, 2008) by Kailash Chadha, PhD Associate Member, Molecular and Cellular Biology (Kerala, India: Research Signpost, 2007) 16 | it’s academic Martin Mahoney, MD, PhD and Arthur Michalek, PhD, FACE In the most extensive review ever of cancer patterns within an American Indian tribal group, RPCI researchers analyzed cancer patterns in the Seneca Nation of Indians for the period from 1955-2004. Led by Arthur Michalek, PhD, FACE, Senior Vice President for Educational Affairs, and Martin Mahoney, MD, PhD, Associate Professor of Oncology, Departments of Medicine and Health Behavior, the study was published in a recent issue of the journal Cancer. The retrospective study examined patterns of cancer incidence in 3,953 males and 4,193 females who were registered tribal members of the Seneca Nation. Cancer incidence rates were based on data collected through a computer match with the New York State Cancer Registry. The study found that, overall, no specific type of cancer was significantly elevated. In fact, both male and female tribal members demonstrated significantly reduced incidences for all cancers combined. In addition, no specific age group showed significantly elevated incidence. A total of 233 primary cancers were diagnosed among Seneca males, with colorectal (20%) and prostate cancers (17%) the most common. Among female members, 256 cancers were diagnosed, with lung (20%) and breast cancer (16%) reported as the most common malignancies. “Among the unique strengths of this study was the reliance on tribal roll books to identify enrolled tribal members and the ability to conduct a comprehensive study over 50 years, leading to the accrual of more than 120,000 person-years of observation,” says Dr. Michalek. “These parameters helped overcome the issues of limited-size populations, which has challenged studies among American Indian tribal groups in the past. Additionally, the leaders of the Seneca Nation demonstrated their trust in Roswell Park researchers and a commitment to the health of their members by allowing researchers access to information required for this comprehensive analysis.” Dr. Mahoney said cancer “remains a relatively rare diagnosis among tribal members, which places some limitation on the interpretation of these results. However, awareness of these unique cancer patterns is of extraordinary value to the Seneca Nation leaders as they determine healthy policy and cancerprevention strategies.” 17 To tap the potential of the “Y Generation” in the fight against cancer, more than a year ago RPCI unveiled its yRoswell campaign, an initiative targeting people born between 1980-1996. The goal: encouraging young people’s interest in science and healthcare careers and galvanizing their volunteer efforts on behalf of cancer research and patient care. Along the way, says Michael Wong, MD, PhD, FRCPC, Department of Medicine, “it became obvious that one of the audiences we were tapping into was the teachers of the Y Generation. Students can always point to a teacher who inspired them to take the next step.” That “aha!” moment, coupled with a request from local teachers for healthcare career information they could share with their students, led to the creation of the Touch Science program at RPCI. Geared toward science teachers in the City of Buffalo’s public schools, Touch Science took off Dec. 6, 2008, with a day-long program at RPCI, where participants explored some of the latest, most exciting technology at RPCI—and tried it out for themselves. Led by RPCI faculty, the event provided an overview of RPCI’s educational programs as well as strategies for giving science-oriented students a head start toward their dreams. Kelly Baudo, Supervisor of Science Education for the Buffalo Public Schools, was among the presenters. Thomas Dougherty, PhD, Chief Emeritus of the Photodynamic Therapy (PDT) Center at RPCI, discussed his role in the development of the laser-based cancer therapy, now in use worldwide. As a chemist who came to RPCI from industry, he’s the personification of the strong link between chemistry and medicine. “The chemistry and physics teachers had a blast with him,” says Catherine Donnelly, RPCI’s Integrated Marketing Communications Manager and coordinator of Touch Science. “They didn’t want to leave.” Dominic Smiraglia, PhD, Cancer Genetics, welcomed teachers to his laboratory and engaged them in a description of “one type of change Geneticist Dominic Smiraglia, PhD, demonstrates a new technique for DNA analysis. 18 | yroswell Tell Me A Story! that occurs in tumor-suppressor genes, called DNA methylation, which generally leads to the silencing of tumor-suppressor genes. Then we studied one common tumor-suppressor gene in breast cancer samples to determine which samples had this methylation event, and we found it in a few samples. Some teachers have lab space and could fairly easily be trained to do these types of experiments.” Ms. Donnelly says RPCI is “still inventing” Touch Science, which currently focuses on three goals: • Enriching science education in the local schools • Promoting health education and a healthy lifestyle to help students reduce their cancer risk • Recruiting students into careers in healthcare and the sciences, especially in the field of oncology “My vision would be to eventually have a Touch Science program in a box,” she says. “We could include videos, a game or quiz show they could use in the classroom, a Prevention quiz and Cancers of the Month quiz.” Right now she offers teachers a “Jeopardy”-style game featuring questions on topics ranging from the history of RPCI to current vaccine research. Steve Indalecio, a science teacher from Harriet Ross Tubman School #31, gave Touch Science two thumbs up: “We do a lot of these workshops throughout the year,” he notes. “This is my eighth year as a teacher, and I can honestly say this is the best workshop I’ve ever attended.” Says Dr. Wong, “We need to engage people, capture their imagination and energy and capture their enthusiasm for teaching children. Great scientists and great physicians will be the end result.” Zap! Thomas Dougherty, PhD, and Adam Sumlin demonstrate what happens to tumor cells with the right mix of laser light and chemicals. Robotics Director Khurshid Guru, MD, lets teachers experience firsthand the on-target precision of robot-assisted surgery. A transcript of a narrative recorded by RPCI Artist-in-Residence Ann Frank during a recent visit on 5W with patient Prudence “Prudy” Georgia RPCI patient Prudy Georgia, seated, with nurse Susan Onetto P rudy watched as I pawed through my cart of art supplies in search of something we could try. Her hands were no longer the swollen claws they were at my last visit, the joints of her fingers no longer purple and hurting from the effects of chemotherapy. She waved her hands at me to show them in their true form. They looked better now, just reddened. But when she turned them over, I could see the peeling flesh on her palms and almost feel for myself the rawness of her tender fingers. Nothing I could offer was soft enough for her to touch comfortably, and even though she seemed curious to try something, we decided to forgo an art project that day to let her healing hands rest. But she invited me to stay anyway, and we chatted about her week and her hopes to go home, maybe after the weekend. As Prudy talked, she watched through the open door the activity at the nurses’ station. She craned to see more: “There goes my nurse.” I wondered if she needed something, but before I could ask, Prudy went on: “Her name is Susan Onetto. The day I decided I was ready to buzz my head, she helped me. I’d had enough; the hair was everywhere, even in my eggs at breakfast. When I told her what I wanted to do, she said, ‘Oh, I can help you with that,’ and she came back with a buzzer and buzzed my head in the shower. Just think of all the things she must have had to do, and she took the time to help me with my hair! I felt so much better, and she did a good job, don’t you think?” She patted her downy head with her sore hands. I agreed. She did look elegant with her new short hair. Prudy continued, “Susan has such an air of competence in everything she does, even the small things—and everything with a smile! When someone takes such care in all they do, big things and small things, it’s a window into their spirit. It says something about who they are. “They’re all like that here. I feel very confident in their care. One day I was coughing, and I gagged a little. I could see them all at the nurses’ station, and six heads turned at once to check on me. ‘I’m okay!’ I told them, quick, before they all ran in. “All the nursing staff, and the aides, too—they don’t shirk anything. Two of them are even pregnant—Cassie and Roxanne. They don’t let that slow them down.” She was impressed with how late into the pregnancy one of the nurses was working—her baby was due very soon—and though the other nurse was not as far along, she was now looking pregnant. It was obviously a welcome distraction for Prudy to be able to share in their joy and anticipation. Frowning a little, Prudy tried to think of more names, muttering about her ‘chemo brain.’ “Do you know Theresa? She can’t help but be a fabulous caregiver.” And she spoke of the nurses’ good humor: “Have you met Roberto? He’s a riot! “The nurses and aides are so joyful here. They work all day, with us all so sick, and they still have fun and make us smile.” feature | 19 “ In Magnet hospitals, patient outcomes are better, and their length of stay is shorter.” L isa Boris, RN, BSN, likes to think of it as “the Nobel Prize for nursing” – and indeed, designation as a Magnet Hospital for Nursing Excellence is an honor earned by fewer than 5% of all hospitals in the U.S. For the first time, RPCI is on a quest for that distinction, given by the American Nurses Credentialing Center (ANCC), the nation’s largest nursing accrediting and credentialing organization. “It’s a rigorous process,” explains Ms. Boris, Nurse Manager of RPCI’s Upper and Lower GI Centers. That’s an understatement! For starters, members of the nursing staff are hard at work on a 3,500-page document that demonstrates how RPCI measures up in 20 different areas of nursing quality that the ANCC calls “forces of magnetism.” Among other points, ANCC reviewers want to see evidence that RPCI nurses understand their roles in the Institute’s mission and vision; that the administration listens to their ideas and fosters a collegial, collaborative atmosphere; that the Institute provides a safe and pleasant work environment for its nurses; and that the care they deliver contributes directly to the highest-quality care for patients. are drawn to RPCI by the emphasis on patient care. “Our nurse-to-patient ratios are excellent,” she explains, “which gives nurses the opportunity to spend time not only on quality care but also to educate patients and families about continued care outside the hospital. We build a partnership with the patient and have better outcomes as a result.” The Institute also encourages its more than 600 nurses to further their education, with pay incentives for earning a master’s degree or PhD, and strong support for nurse-led research. “Some of the best ideas come from our frontline, bedside nurses,” says Ms. Boris. “They see firsthand the needs of our patients, and they’re making a difference in research. The administration is telling them, ‘Your ideas matter.’” Ms. Kelly adds that the ANCC will also examine nurses’ credentials, from the degrees they hold to the numbers of Continuing Education units they have earned. After the application package is delivered February 1, 2010, the ANCC will begin evaluating how well RPCI fulfills the 20 “forces of magnetism.” If the document passes muster, an ANCC accreditation team will conduct a three-day site visit to ask candid questions of the nurses and other RPCI staff about the Institute’s nursing model. “We have to show strong collaboration between the Department of Nursing and the entire institution in achieving positive patient outcomes,” says Mary Ann Long. “Ultimately, that’s what Magnet is about.” Ms. Kelly notes that data gathered for the Magnet self-evaluation document will serve as benchmarks for continued improvement in nursing at RPCI, and will form “a plan of action for the coming years.” While accreditation is granted for a four-year period, she adds, retaining Magnet status will require continual evaluation, both internally and by the ANCC. Lisa Boris is confident of the outcome. “There’s nowhere better to go for cancer care than Roswell Park, and our nursing care reflects that,” she says proudly. “We already know that. We want everyone else to know it, too.” Patients are the primary beneficiaries of the Magnet label, because it helps them identify hospitals where they’ll receive the best care. “In Magnet hospitals, patient outcomes are better, and their length of stay is shorter,” notes Maureen Kelly, RN, MS, RPCI’s Vice President of Patient Care Services and Chief Nursing Officer. “U.S. News & World Report has added Magnet status as one of the indicators for measurement of the top 100 cancer centers and top 100 hospitals in the U.S.” The Magnet seal of approval is also a beacon for talented nurses who are looking for the best places to work, and Ms. Boris notes that RPCI already has solid proof that it belongs in that category. “We have a waiting list of people who want to come here,” she says. One major attraction: the option of working three 12-hour days followed by four days off—an arrangement that grew from the nurses’ request for “a work-life balance.” Mary Ann Long, RN, MS, RPCI’s Director of Patient Care Services and Magnet Director, says the waiting list includes both recent grads and nurses with extensive experience, who 20 | feature 21 ’s Visiting Professor in Oncology Program Ian Thompson, MD, Professor and Endowed Chair of the Department of Urology at the University of Texas Medical Center, Vice Chair of the National Cancer Institute’s Early Detection Research Institute, and newly named Chair of the Genitourinary Committee of the Southwest Oncology Group, visited RPCI recently as Visiting Professor in Oncology under the auspices of Pfizer’s highly competitive Medical and Academic Partnerships grants program. RPCI was one of only eight institutions nationwide to win grant support for a three-day visit by a distinguished expert in oncology. L. to r.: Kay Seekamp, RN, Pfizer, Inc.; James Marshall, PhD; Peter Steffan, Pfizer; Ian Thompson, MD; and Brad Salmon Pfizer, Associate Director, Clinical Protocol Manager, Pfizer Oncology Dr. Thompson is also Clinical Associate Professor in the Department of Surgery/Uniformed Services of Health Sciences, Department of Surgery, Bethesda, MD. His RPCI visit focused on the prevention, detection and management of prostate cancer; cancer screening; and chemoprevention strategies. James R. Marshall, PhD, Senior Vice President, Cancer Prevention and Population Sciences, and James Mohler, MD, Chair of Genitourinary Surgery at Roswell Park, were local hosts to Dr. Thompson. The Visiting Professor in Oncology program is designed to advance oncology by creating opportunities for educational visits by prominent cancer experts to U.S. medical schools/ teaching hospitals and cancer centers. Grant recipients are chosen by an independent academic advisory board of experts in the oncology field. Dr. Thompson lectured and met with Urology residents and fellows and with Urology and Prevention faculty at both the University at Buffalo and Roswell Park. Oh, the Places You’ve Gone! (FAC) Clara M. Ambrus, MD, PhD, FACP, and Julian L. Ambrus, MD, PhD, FACP, have been awarded the American College of Physicians (ACP) Laureate Award, given for “abiding commitment to excellence in medical care, education, research, or service to their community, chapter, and ACP. Awardees are physicians with a long history of excellence and peer approval in their specialty of internal medicine.” Julian Ambrus is also President-Elect of the Catholic Academy of the Sciences, Washington, DC. (FAC) John Cowell, PhD, Associate Director for Basic Science and Professor of Pathology in Medical College of Georgia Cancer Center, has been named a Georgia Cancer Coalition Distinguished Cancer Scholar. He served previously as Chair of Cancer Genetics at RPCI. (PhD) Andrew Freedman, PhD, of the National Cancer Institute’s Division of Cancer Control and Population Sciences, was co-leader of a team that developed one of the first colorectal cancer absolute risk assessment models. Available online at www.cancer.gov/ColorectalCancerRisk, the tool was the subject of a recent article in the NCI Cancer Bulletin (www.cancer.gov/ncicancerbulletin/011309/page3). (FAC) Douglas E. Williams, PhD, has been promoted from President to CEO of ZymoGenetics, Inc., Seattle, Washington. ZymoGenetics discovers and develops novel protein therapeutics based on the company’s research and biological insights into key disease pathways. Congratulations! Nicholas Petrelli, MD, FACS, former Chair of Surgery at RPCI, congratulates Roswell Park Alliance founders Anne and Donna Gioia, who received the Society of Surgical Oncology’s James Ewing Layman’s Award at the 62nd Annual Cancer Symposium. Anne and Donna, who were honored for their passionate leadership and advocacy, join a stellar roster of awardees, including General H. Norman Schwarzkopf and the late Ann Landers. (FAC) Michael McGarry, PhD, is Vice President of Preclinical Studies at Medelis, Inc., an oncology contract research organization based in Phoenix, AZ. Join us for the following Faculty Forum lectures, each presented from 8-9 a.m. in the Zebro Family Conference Room of RPCI’s Center for Genetics and Pharmacology. Physician participants will be awarded AMA Category 1 credit. May 20 June 3 July 22 Mihich Lecture, “Mechanisms and Therapeutic Targeting of the Tumor Microenvironment,” with Douglas Hanahan, PhD, Professor of Biochemistry, University of California at San Francisco Director’s Conference, “Monoclonal Antibody Therapy of Cancer: Making Better Antibodies, and Making Antibodies Better,” with George Weiner, MD, Director of the Holden Comprehensive Cancer Center at The University of Iowa Cori Lecture, “Translational Control of Cancer,” with Nahum Sonenberg, PhD, the James McGill Professor of the Rosalind and Morris Goodwin Cancer Centre, McGill University, Montreal, and Recipient of the 2008 Canada Gairdner International Award, given for his pioneering discoveries in cellular translation of genetic information. May 27 “Dissecting Human Genomes to Understand ‘Stemness’ and Cancer,” with Gennadi V. Glinsky, MD, PhD, Head of the Translational and Functional Genomics Laboratory, Ordway Cancer Center, Albany, NY 22 | forum&function June 10 Weiss Memorial Lecture, “Targeting the Intrinsic Therapeutic Resistance of Breast Cancer Tumor-Initiating Cells,” with Jeffrey Rosen, PhD, the C.C. Bell Professor, Department of Molecular & Cellular Biology, Baylor College of Medicine (MS) Herbert Newton, MD, FAAN, is Professor of Neurology and Oncology, and Director of the Division of Neuro-Oncology, Department of Neurology, of The Ohio State University Medical Center and the James Cancer Hospital. He holds the Esther Dardinger Chair in Neuro-Oncology and serves as Co-Director of the Dardinger Neuro-Oncology Center at the James Cancer Hospital. In photo (above, l-r) are Anne Gioia; Candace Johnson, PhD, Deputy Director, RPCI; Dr. Petrelli, Medical Director, Helen F. Graham Cancer Center, Christiana Care Health Services; Donna Gioia; and Cindy Eller, Vice President, Development, RPCI. KEY: SMR (Summer Reserach Program); PhD (Doctoral Program); PDoc (Postdoctoral); MS (Master’s Degree Program); STF (Staff); FAC (Faculty); FLW (Fellow); RES (Resident) I just received the RPCI alumni magazine [which featured an article about West Point cadets who participated in a summer study program at RPCI]. Thanks so much for the positive press and continuing support. In late October, each cadet presented to our faculty about their RPCI research and experience over the summer. It inspired a few cadets to consider the option for next summer, and feedback from the faculty was great. Thanks and best wishes. Melissa R. Eslinger, MAJ, LG You can connect to your RPCI colleagues on a number of Social Networking sites—including LinkedIn®, Twitter, Facebook and myspace. Assistant Professor, Course Director, Genetics U.S. Military Academy, West Point classnotes | 23 Photo courtesy of Lockport Union Sun & Journal The Road Less Traveled Dr. Natalie Zeitouni in St. Lucia Every year, more than 300,000 vacationers flock to the Caribbean island of St. Lucia to hike through the exotic rainforest and lounge on the sunny beaches. But Dr. Nathalie Zeitouni, Interim Chair of Dermatology at RPCI, set her sights on a different destination when she traveled to St. Lucia recently with the nonprofit group Health Volunteers Overseas (HVO). “I want to help these people as much as I can, and I’m at a point in my career where I’ve done a lot, so now I can volunteer in an area that I know well—dermatology.” 24 | extracurriculars At St. Jude Hospital, near Vieux-Fort, on the island’s southern coast, she cared for patients ranging from the very young to the very old, and shared her expertise in dermatology with physicians, residents and nurses. She also delivered gifts of medications and certain medical supplies provided by Howard Stoll, Jr., MD, who retired recently from RPCI’s Dermatology Department. Clothing and small gifts were presented to children living in an orphanage near Vieux-Fort. At Roswell Park, Dr. Zeitouni specializes in Mohs surgery and leads research on unusual skin tumors, the use of photodynamic therapy for treating cutaneous carcinomas, and the identification of risk factors and development of treatment guidelines for rare skin cancers. Because her time in St. Lucia was limited, she focused partly on teaching the medical staff, “so they can take care of their own patients.” Dr. Zeitouni hopes to volunteer with HVO again in the future, perhaps in Peru or another area where the program places an even greater emphasis on teaching. “I’ve always wanted to give back,” she says. “I want to help these people as much as I can, and I’m at a point in my career where I’ve done a lot, so now I can volunteer in an area that I know well—dermatology.” Three-year-old Rory “saddles up for Roswell” with a hand from his mom, Tracey O’Connor, MD (right), and Jeffrey Durbin. An MD With Horse Sense “When you’re riding, you can’t think about anything else. When I’m taking a challenging lesson, I can’t think about my kids or what I have to do at home or even my patients—and that’s good.” G rowing up in Indiana, Tracey O’Connor was among a group of “extremely enthusiastic little girls” who took riding lessons at a local livery stable. “I would do that once a week, and then every Christmas nag my parents to buy me a pony, and every Christmas night, I would cry because it didn’t happen,” recalls Dr. O’Connor, Attending Physician in RPCI’s Department of Medicine. But persistence paid off: “When I was 11, my mother finally nagged my father into getting me a pony of my own.” Today Dr. O’Connor rides a horse instead of a pony, and her love of riding is stronger than ever. “It’s so engrossing,” she says. “When you’re riding, you can’t think about anything else. When I’m taking a challenging lesson, I can’t think about my kids or what I have to do at home or even my patients—and that’s good.” Dr. O’Connor’s equestrian interests led to her friendship with Sue and Terry Williams, owners of the Chestnut Ridge Equestrian Center in Gasport, New York, where her horse, Providence, is stabled. Terry died of colon cancer not long after he and Sue founded Saddle Up for Roswell, a riding event that has raised more than $25,000 to date for the Roswell Park Alliance Foundation. Dr. O’Connor, a sponsor, has competed in the event every year, along with scores of other participants who understand the dynamic between horse and rider. “Horses are unpredictable animals,” says Dr. O’Connor. “They have minds and feelings and personalities of their own. You develop relationships with them over time, and when they give you what you’re asking them to do, even though it may be difficult for them, that’s a great feeling.” 25 NON-PROFIT ORG. U.S. POSTAGE Return Service Requested PAID BUFFALO, NEW YORK PERMIT NO. 61 Doctors Rank Roswell Park Among Nation’s Top Cancer Hospitals World’s Largest Circulation Magazine Roswell Park Cancer Institute ranks among the nation’s top specialty hospitals for general cancer care on a list to be published in the May/June 2009 issue of AARP The Magazine. The publication has the largest circulation of any magazine in the world, with more than 34 million readers. The list also includes: • University of Texas M.D. Anderson Cancer Center, Houston, TX • Memorial Sloan-Kettering Cancer Center, New York City • Dana-Farber Cancer Institute, Boston, MA • Mayo Clinic, Rochester, MN • City of Hope, Duarte, CA • The Johns Hopkins Hospital, Baltimore, MD • Duke University Hospital, Durham, NC The list was compiled by Consumers’ Checkbook, an independent, nonprofit consumer service organization that rates everything from cars and appliances to veterinarians, credit cards, and pest-control firms. Recognizing that growing numbers of patients are traveling outside their communities in order to receive the best health care, Consumers’ Checkbook polled doctors across the nation to find out where they would be most likely to send patients who needed specialized care. The resulting list, called “Doctors’ Faves” on the AARP website, includes doctors’ picks for the best hospitals for general cardiac care, general cancer care, mystery diagnoses, neurosurgery, and eye care. The list can be found online at www.aarpmagazine.org/health/right_hospital_for_you.html
© Copyright 2024